Anavex Life Sciences Corp (AVXL)

[georgejjl]

From this comes one of the great mischaracterizations of simufilam’s results: namely that such improvements in cognitive scores had never been seen before. For Anavex (AVXL) 2-73, the improvement in MMSE scores at 57 weeks was two points and at 70 weeks it was 3 points (and was still close to baseline at 148 weeks). The results from phase 3 clinical drug trials for Anavex will be known before those for simufilam. If the two drugs produce the same results in phase 3 clinical trials as they did in their open-label trials, Anavex 2-73 should be the drug that the FDA approves for the treatment of the disease.

https://seekingalpha.com/article/4479121-cassava-sciences-credibility-issues

Good luck and GOD bless,